---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-007620"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:54:47.514301+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity settles SEC probe over FDA disclosures; pays $2.5M civil penalty

## Summary
- Final settlement with SEC: administrative cease-and-desist order, no admission or denial of findings.
- Civil penalty of $2.5 million; cash runway into 2026 unchanged per prior guidance.
- Resolves investigation into past disclosures about FDA interactions regarding Dovitinib NDA (2021).
- All outstanding legal matters now concluded, including securities class action dismissed Feb 2025.
- Company reaffirms focus on stenoparib Phase 2 trials in ovarian and small cell lung cancer.

## SEC filing metadata
- accession: 0001437749-25-007620
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925007620/0001437749-25-007620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925007620/allr20250313_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-007620
- JSON: https://secwatch.observer/filing/0001437749-25-007620.json
- Plain text: https://secwatch.observer/filing/0001437749-25-007620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.